论文部分内容阅读
目的研讨糖尿病伴发高血压患者运用厄贝沙坦药物治疗的临床价值。方法从我院2014年1月-2016年1月选取400例糖尿病伴发高血压患者进行随机非盲法分组试验,两组各200例,Ⅰ组接受氨氯地平片口服,Ⅱ组在上述用药下接受厄贝沙坦治疗,比较和评估该两种方案对血压与血糖的改善情况等。结果Ⅱ组接受治疗后的SBP、DBP指标值相比Ⅰ组均显著降低,统计学成立(P<0.05),而FPG与2h PBG指标的比较,两组相差不大,统计学不成立(P>0.05)。两组在试验期间均未产生明显的毒副反应。结论对糖尿病伴发高血压患者运用厄贝沙坦治疗,降压效果安全、理想,且基本不会对血糖水平造成影响,值得推荐。
Objective To study the clinical value of irbesartan in patients with diabetes mellitus and hypertension. Methods From January 2014 to January 2016 in our hospital, 400 cases of diabetic patients with hypertension were randomly divided into two groups, 200 cases in each group. Patients in group Ⅰ received amlodipine tablets orally, while those in group Ⅱ received the above medication Under the irbesartan treatment, comparison and evaluation of the two programs on blood pressure and blood glucose and improve the situation. Results The SBP and DBP index of group Ⅱ were significantly lower than those of group Ⅰ (P <0.05), while the difference of FPG and 2h PBG was not significant (P> 0.05). Both groups did not produce significant toxicity during the experiment. Conclusion Irbesartan treatment in patients with diabetes mellitus and hypertension is safe and ideal, and the blood sugar level will not be affected basically, which is worth recommending.